Variant · Insertion
EGFR E746_S752insV
CI-VAR-00000837Explore in graph →CIViC 4280
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 17877814
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma1 | ||||||||
| EGFR E746_S752insV | Erlotinib | Predictive | D | Supports Sensitivity Response | 1 | submitted | EID4232In an in vitro study, a Ba/F3 cell line expressing EGFR E746_S752insV demonstrated increased sensitivity to erlotinib treatment (IC50=25nM), comparable to Ba/F3 cells expressing EGFR L858R (a known se… (full text at CIViC) PMID 17877814 · de Gunst et al., 2007 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available